The role of F18-fluorodeoxyglucose positron emission tomography in guiding diagnosis and management in patients with known or suspected cardiac sarcoidosis
Brian A. Mc Ardle(MACOM (United States)), Pablo B. Nery(University of Ottawa), Rob Beanlands(University of Ottawa), Myra Cocker(University of Ottawa), Robert A. deKemp(University of Ottawa), Hiroshi Ohira(University of Ottawa), David H. Birnie(University of Ottawa), E. Leung(University of Ottawa), Jean N. DaSilva(Centre Hospitalier de l’Université de Montréal)
Cited by 87
Related Papers
Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart Failure
|New England Journal of Medicine|2010|1.8k
Impaired Myocardial Flow Reserve on Rubidium-82 Positron Emission Tomography Imaging Predicts Adverse Outcomes in Patients Assessed for Myocardial Ischemia
|Journal of the American College of Cardiology|2011|602
Anatomic Versus Physiologic Assessment of Coronary Artery Disease
|Journal of the American College of Cardiology|2013|563
The Use of <sup>18</sup>F-FDG PET in the Diagnosis of Cardiac Sarcoidosis: A Systematic Review and Metaanalysis Including the Ontario Experience
|Journal of Nuclear Medicine|2012|512
F-18-Fluorodeoxyglucose Positron Emission Tomography Imaging-Assisted Management of Patients With Severe Left Ventricular Dysfunction and Suspected Coronary Disease
|Journal of the American College of Cardiology|2007|476